Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Solid Tumors Harboring KRAS Mutation With Imatinib and Trametinib

NCT06962254 is registered in ClinicalTrials.gov with China Medical University Hospital as lead sponsor.

NCT NCT06962254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06962254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Solid Tumors Harboring KRAS Mutation With Imatinib and Trametinib
Lead sponsor
China Medical University Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
May 10, 2025
Completion date
March 31, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor cancer